Author

Campbell McInnes

University of South CarolinaORCID 0000-0002-5592-9082Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Assay:protein structure· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

C.N.R. RaoiD· 2 shared Michael D. WyattiD· 2 shared Ariel MadrigaliD· 1 shared Bürge UlukaniD· 1 shared Cassidy E Socia· 1 shared Danda P. ChapagaiiD· 1 shared Elizabeth Hill· 1 shared Elmar NurmemmedoviD· 1 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C.N.R. RaoORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Lysyl oxidase drives ccRCC progression by coordinating HIF-2α transcription program with tumor microenvironment

Bürge Ulukan, Özge Saatci, Ariel Madrigal, Minjun Kim, Wensheng Tian, Mustafa Soytaş, Zohreh Mehrjoo, Ozlem Sener Sahin, Kukkamadi Sreenivas, C.N.R. Rao, Tamiko Nishimura, Virginie Pillon, Jean-Sebastian Anoma, Elizabeth Hill, Janusz Rak, , Ozgur Sahin

This study identifies LOX as a driver of ccRCC progression by sustaining HIF-2α transcription and modulating the tumor microenvironment.

bioRxiv · Jul 27, 2026 · PreprintCancer Biology

Abbapolin inhibitors of the PLK1 PBD as Prostate Cancer Therapeutics, in vivo activity and synergy with androgen therapy

George Merhej, Gurusankar Ramamoorthy, Danda P. Chapagai, Mohammad Esfini Farahani, Yifan Kong, C.N.R. Rao, Jessy M. Stafford, Zachary T. Mack, Cassidy E Socia, S Krishna Kumari, Kristen Hogan, Niti Jan, Maria Marjorette Pena, Elmar Nurmemmedov, Ivan Babić, , Campbell McInnes

This study develops and characterizes abbapolins, non-peptidic PLK1 PBD inhibitors, showing in vivo efficacy against prostate cancer and synergy with enzalutamide.

bioRxiv · Jul 24, 2026 · PreprintCancer Biology

Insights into the Structural Regulation of Polo-Like Kinase Activity using AlphaFold

Michael D. Wyatt, Campbell McInnes

This paper uses AlphaFold to analyze the structural regulation of Polo-Like Kinase (PLK) activity, revealing domain arrangements and interactions that explain activity regulation and phosphopeptide selectivity.

bioRxiv · Oct 21, 2024 · PreprintBiochemistry